Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Bio-Path Holdings Inc
BPTH | US
0.06
USD-0.00
-1.50%
BPTH | US
About Bio-Path Holdings Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
06/03/2026
Close
0.06
Open
0.06
High
0.06
Low
0.06
Bio-Path Holdings Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize a drug delivery and antisense technology platform that uses P-ethoxy which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer non-small cell lung cancer and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings Inc. was founded in 2007 and is based in Bellaire Texas.
View LessBPTH | US
Risk
128.3
Sharpe
-0.49
Luna's Score
46/100
Recommendation
Hold
Luna says (BPTH | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
131.8%1 month
128.3%3 months
165.4%6 months
168.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.29
Debt to equity
0.04
Debt to assets
0.01
Ent. to EBITDA
0.03
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-12.98M
MarketCap
150.83K
MarketCap(USD)
150.83K
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-366.18
Short ratio
0.11
Short perc.
0.38
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.01
Range1M
0.01
Range3M
0.05
Volumes: Market Activity
Rel. volume
0.04
Price X volume
31.03
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.03 | 24.85 | Cheaper |
| Ent. to Revenue | - | 361.91 | - |
| PE Ratio | - | 30.05 | - |
| Price to Book | 2.29 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 165.38 | 65.24 | Riskier |
| Debt to Equity | 0.04 | -1.88 | Expensive |
| Debt to Assets | 0.01 | 0.48 | Cheaper |
| Market Cap | 150.83K | 3.71B | Emerging |
